异烟肼预防治疗对结核感染与疾病进展的影响
在秘鲁利马开展纵向队列研究,纳入微生物学确诊肺结核成人及其家庭接触者。异烟肼预防治疗与5岁以下接触者6个月TST阳转无关,但与所有年龄接触者进展为结核病的风险降低相关,5岁以下者效果更明显。
要点
- IPT未降低5岁以下家庭接触者6个月TST阳转风险。
- IPT与所有年龄家庭接触者进展为结核病风险降低相关。
- 5岁以下接触者中IPT对进展为结核病的保护作用更明显。
核心结论
- 异烟肼预防治疗与5岁以下儿童TST阳转无关,但与家庭接触者进展为结核病风险降低强烈相关。
研究设计与样本
- 在秘鲁利马开展的纵向队列研究,纳入微生物学确诊肺结核成人及其家庭接触者。
主要发现
- 指示病例空洞性疾病与TST阳转风险增加相关。
临床怎么用
- 对家庭接触者启动IPT可降低进展为结核病的风险,尤其5岁以下儿童获益更明显。
- IPT不应被预期降低5岁以下儿童6个月TST阳转率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Tuberculosis (TB) causes major morbidity and mortality among children worldwide. Isoniazid preventive therapy (IPT) protects against progression to TB disease, but its effect on preventing new TB infection remains uncertain. METHODS: We conducted a longitudinal cohort study in Lima, Peru, enrolling adults with microbiologically confirmed pulmonary TB and their household contacts (HHCs). We assessed HHCs at baseline and 6 months for TB infection using tuberculin skin testing (TST) and for TB disease through clinical evaluation. We assessed 2 outcomes in relation to IPT initiation: TB infection among HHCs under 5 years of age, indicated by an increase in TST induration of ≥6 mm from baseline to 6 months, and progression to TB disease among HHCs of all ages, diagnosed between 15 days and 12 months after enrollment. RESULTS: Among 666 under-5-year-olds included assessed for TST conversion, 361 (54.2%) had initiated IPT. Overall, 103 (15.5%) converted at 6 months; IPT initiation was not associated with conversion (adjusted OR 1.01; 95% CI, .64-1.59). Index participant cavitary disease was associated with an increased risk of conversion. In contrast, IPT initiation was associated with reduced risk of progression to TB disease among 14 032 HHCs of all ages (adjusted HR 0.45; 95% CI, .32-.64) with more pronounced efficacy among under-5 seconds (adjusted HR 0.19; 95% CI, .10-.36). CONCLUSIONS: Isoniazid preventive therapy was not associated with reduced TST conversion among children under 5 years, but it was strongly associated with reduced progression to TB disease among HHCs of all ages.
引用
- Zazueta OE, Becerra MC, Galea JT, et al. The Impact of Isoniazid Preventive Therapy on Tuberculosis Infection and Disease Progression. Clin Infect Dis. 2026. PMID: 42605523. doi:10.1093/cid/ciag483
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。